Antiproliferative actions of inhalational anesthetics: comparisons to the valproate teratogen

被引:20
作者
O'Leary, G
Bacon, CL
Odumeru, O
Fagan, C
Fitzpatrick, T
Gallagher, HC
Moriarty, DC
Regan, CM [1 ]
机构
[1] Univ Coll Dublin, Conway Inst, Dept Pharmacol, Dublin 4, Ireland
[2] Mater Misericordiae Hosp, Dept Anesthesia, Dublin 7, Ireland
关键词
D O I
10.1016/S0736-5748(99)00109-4
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The antiproliferative potential of the volatile anesthetics isoflurane, enflurane and sevoflurane was determined and compared to the valproate teratogen. The in vitro system employ ed. a G1 phase proliferative arrest endpoint in C6 glioma, has served previously to discriminate agents with known teratogenic potential in vivo. Based on estimated IC50 values that were within twice the estimated minimum aveolar concentration value, the rank antiproliferative potency of the inhalational anesthetics employed was isoflurane = enflurane >> sevoflurane. Flow cytometric analysis of growth-arrested cell populations failed to reveal specific accumulation in any cell cycle phase and the lack of a G1 phase-specific effect was confirmed by the absence of a transient, time-dependent sialylation event in synchronized cells, The antiproliferative mechanism of volatile anesthetics, and valproate, was mediated at hydrophobic binding sites, as increasing the hydration sphere of the drug-micelle complex, using the hygroscopic qualities of the dimethylsulfoxide vehicle, completely reversed this effect. Our findings suggest inhalational anesthetics lack the specific in vitro characteristics of the valproate teratogen. (C) 2000 ISDN. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:39 / 45
页数:7
相关论文
共 26 条
[1]   Cell proliferation, migration and CAM-dependent neurite outgrowth as developmental in vitro endpoints for screening teratogenic potential: Application to valproic acid and related analogues of varying potency [J].
Bacon, CL ;
Berezin, V ;
Bode, G ;
Bock, E ;
Bojic, U ;
Doherty, P ;
Ehlers, K ;
Ellerbeck, U ;
Julien, P ;
Kawa, A ;
Maar, TE ;
Nau, H ;
Pirovano, R ;
Regan, CM ;
Schousboe, A ;
Spezia, F ;
Walsh, FS ;
Williams, EJ .
TOXICOLOGY IN VITRO, 1998, 12 (02) :101-109
[2]   Valproic acid suppresses G1 phase-dependent sialylation of a 65 kDa glycoprotein in the C6 glioma cell cycle [J].
Bacon, CL ;
ODriscoll, E ;
Regan, CM .
INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 1997, 15 (06) :777-784
[3]   Teratogenic potency of valproate analogues evaluated by quantitative estimation of cellular morphology in vitro [J].
Berezin, V ;
Kawa, A ;
Bojic, U ;
Foley, A ;
Nau, H ;
Regan, C ;
Edvardsen, K ;
Bock, E .
TOXICOLOGY IN VITRO, 1996, 10 (05) :585-594
[4]  
BJERKEDAL T, 1982, LANCET, V2, P1096
[5]  
BOJIC U, 1998, EUR J PHARMACOL, V54, P2889
[6]   SURGERY DURING PREGNANCY AND FETAL-OUTCOME [J].
BRODSKY, JB ;
COHEN, EN ;
BROWN, BW ;
WU, ML ;
WHITCHER, C .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1980, 138 (08) :1165-1167
[7]   INOSITOL DEFICIENCY INCREASES THE SUSCEPTIBILITY TO NEURAL-TUBE DEFECTS OF GENETICALLY PREDISPOSED (CURLY TAIL) MOUSE EMBRYOS INVITRO [J].
COCKROFT, DL ;
BROOK, FA ;
COPP, AJ .
TERATOLOGY, 1992, 45 (02) :223-232
[8]  
COPP AJ, 1988, DEVELOPMENT, V104, P285
[9]   Correlation of in vitro anti-proliferative potential with in vivo teratogenicity in a series of valproate analogues [J].
CourageMaguire, C ;
Bacon, CL ;
Nau, H ;
Regan, CM .
INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 1997, 15 (01) :37-43
[10]  
CourageMaguire C, 1997, INT J DEV NEUROSCI, V15, P693